Ascentage Pharma Group International (NASDAQ:AAPG) Sees Strong Trading Volume – Here’s Why

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares saw strong trading volume on Wednesday . 9,503 shares were traded during mid-day trading, an increase of 117% from the previous session’s volume of 4,372 shares.The stock last traded at $17.80 and had previously closed at $18.45.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. BTIG Research reaffirmed a “buy” rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Monday, April 13th. China Intl Cap raised Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, April 6th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on Ascentage Pharma Group International in a research note on Friday, April 24th. They set a “buy” rating and a $40.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company’s stock. According to data from MarketBeat, Ascentage Pharma Group International currently has an average rating of “Buy” and a consensus target price of $46.67.

Ascentage Pharma Group International Trading Down 3.5%

The company has a fifty day simple moving average of $23.01 and a two-hundred day simple moving average of $25.64. The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The business had revenue of $24.72 million during the quarter. On average, research analysts expect that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ascentage Pharma Group International

Several large investors have recently bought and sold shares of the stock. UBS Group AG increased its holdings in shares of Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares during the last quarter. XY Capital Ltd increased its holdings in shares of Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after acquiring an additional 12,530 shares during the last quarter. Hsbc Holdings PLC purchased a new position in shares of Ascentage Pharma Group International in the 2nd quarter valued at about $391,000. Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International in the 3rd quarter valued at about $383,000. Finally, ABC Arbitrage SA purchased a new position in shares of Ascentage Pharma Group International in the 3rd quarter valued at about $204,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.